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Immunoaff inity Cl-~romatography 
Anuradha Subramanian 
1. Introduction 
Recent devclopments in recombinant DNA technology have enabled the 
synthesis of valuable therapeutic proteins in bacterial cells as well as in novel 
eucaryotic expression systems. However, the purification of proteins of inter- 
est from either the conventional sources, cell culture, or novel routes in a highly 
purified form necessitates the development of separation tcchniques capable of 
recovering proteins from these feed streams in a highly purified form (1,2). 
Purification of therapeutic proteins from biological sources is usually compli- 
cated by the presence of endogenous proteins (2). Purification methodologies 
based on ion exchange or adsorption serve as excellent prepurification steps, 
but they fail to resolve complex protein mixtures to yield a homogeneous pro- 
tein product (l). Purification techniques based on affinity interactions between 
molecules (i.e., immunoaffinity chromatography, IAC) have rapidly evolved 
using a variety of biological and synthetic ligands (2). 
1. I .  lmmunoaffinity Chromatography 
Itnmunoaffinity chromatography is a process in which the binding affinity 
of an antigen (Ag) to a parent antibody (Ab) is utilized as a basis of separation. 
The antibody specific to the protein of interest is immobilized onto a rigid solid 
support to yield an active immunosorbent. A complex mixture of proteins is 
then passed over the immunosorbent whereby the antibody captures the pro- 
tein of interest and the other nonproduct proteins are washed away in the col- 
umn fall through (1,s). The reversible interaction between the antigen and 
antibody can be disrupted to yield a highly purified product in the column elu- 
ate (2). This could be achieved by changes in pH or use of chaotropes such 
sodium or potassium thiocyanateslureas as eluents. Due to the customized avid- 
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ity and specificity, n~onoclonal antibodies (mAbs) have become indispensable 
for both protein characterization and purification (5). 
Irn~nunoglobulin (IgG) is an approximately 150,000 Dalton molecular 
weight glycoprotein. The association constant for the binding of antigens to 
antibodies (free to bound) is about 10-~-10-'~ M. The symmetry of the Fab frag- 
ments on the antibody molecule predetermines a theoretical antigen binding sto- 
ichiometry of 2: 1 (molar basis) (3). Pritnary amines (lysine residues) are found 
throughout the antibody molecule, whereas carbohydrate (CHO) moieties are 
mainly found in the Fc region. Most of the linker chemistries engineer covalent 
attachment of the antibody via the primary amines or the C H 0  residues. 
1.2. Support Characteristics 
The ~~nmunosorbent performance is dependent on the support matrix on 
which the antibody is irnn~obilized. Efficient immunosorbents should possess 
mechanical/physical stability, good flow properties, acceptable pressure drop, 
nlinimal nonspecific binding, surface area for Ab-Ag interactions, and chemi- 
cal stability (10). Polymeric andlor agarose based supports are extensively used 
in affinity chromatography. Both of the aforementioned supports lend them- 
selves to a variety of conjugation chemistries and offer reasonable physical1 
mechanical properties and are resistant to the various solvent systems used in 
affinity chromatography. The functioning of an immunosorbent column is 
dependent on the activation chemistry used to couple the antibody to the matrix. 
2. Materials 
2.1. Chromatographic Columns 
Use jacketed columns from Pharmacia Biotech. These glass columns come 
in different sizes complete with flow adaptors, jackets, and fittings. Please read 
the instructions accompanying these columns for proper assembly. 
2.2. General Laboratory Equipment 
1. Bench-top laboratory centrifuge (operating speed 500-1000 rpm) 
2. End-to-end rotator 
3. Polypropylene bottles (Nalgene) 
4. Masterflex peristaltic pumps 
2.3. Reagents 
Activated matrices supporting different activation chemistries are c 
available and can be purchased from appropriate vendors. Emphaze 
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2.4. Apparatus 
Assemble  a chromatographic station required fo r  running the I A C  that 
includes a peristaltic pump (Masterflex, Cole-Palmer), which supports flow rates 
between 0.5-5 mLIinin, a flow-through UV-absorbance monitor (Bio-Rad or 
Rainin), chart recorder, columns with flow adaptors, and a fraction collector. 
Configure the system t o  enable sequential delivery of the feed and buffers through 
the pump, column, UV detector and fraction collector (see Fig. 1). 
2.5. Antibody Sample Preparation 
l .  For a lyophilized antibody, dissolve the antibody in an antibody-coupling buffer. 
Make sure that the lyophili~ation buffer does not contain amines such as glycine 
or Tris. 
2. For an antibody in solution (samplcs in buffers, IgG fractions, and so forth): 
Make sure that the antibody solution does not contain primary amines such as 
Tris or glycine. Remove any primary amines present by dialysis 01 gel filtration. 
2.6. N-Hydroxysuccimide (NHS) Activation 
1. NHS activated matrix (Note: Activated beads are supplied as a suspension in 
ethanol as 5070 (v/v) solution). 
2. Antibody-coupling buffer (0.1 M 4-mortholinepropanesulfonic acid (MOPS), 0.1 M 
NaCI, pH 7.2). 
3. Blocking buffer ( l  M ethanolamine, pH 8.0). 
4. Ligand-loading buffer (10 n M  Tris-HC1, 50 mM NaCl, pH 6.8). 
5. Distilled water (Keep cold at 4°C.). 
1. Emphaze activated matrix. 
2. Antibody-coupling buffer (0.05 M sodium phosphate, 0.75 M Na,S04, pH 7.0). 
3. Blocking buffer ( l  M ethanolamine in 0.05 M sodium pyrophosphate, pH 9.3). 
4. Ligand-loading buffer ( l 0  mM Tris-HC1, 50 mM NaC1, pH 6.8). 
3. Methods 
3.1. Coupling Through Primary Amino (-NHd Groups 
3.1. l. NHS Activation 
1. Invert the bottles containing the activated matrix gently to obtain a well-mixed 
slurry. Pour 500 n1L of well-mixed slurry on a sintered glass funnel and then suck 
the liquid through by gentle vacuum suction. This amount of slurry will yield a 
final sorbent volume of 250 mL. Stir the suspension with a glass rod to disperse 
the gel and take care to keep the gel moist at all times. 
2. Wash the activated resin with 1.5 L of ice cold distilled water.. Repeat the wash 
step four to five times with distilled water to ensure the removal of ethanol. Drain 
water using gentle vacuum and transfer the moist gel to a 2-L Erlenmeyer flask 
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Fig. l .  Chromatographic apparatus and setup. 
containing 1000 mL of a 3-5 mg/mL of antibody solution in coupling buffer. 
Carry out t h ~ s  tep In the cold room. Place a medium-sized magnetic stlr In the 
flask. Place the flask w ~ t h  the contents on a shaker and mix the contents on low 
speed for 24 h in the cold room or for 4 h at room temperature. Avoid '1 'g orous 
shaking as that may lead to mechanical damage of the act~vated matrix (see Fig. 
2 for antibody coupling reaction). 
3. Allow the gel to settle after completion of the coupling step (i.e., step 2) at 
room temperature (RT). Remove the supernatant by aspiration or decanting. 
Use care to retain beads in bottle. This supernatant should be saved for the 
determination of the amount of uncoupled antibody. The chemical compound 
released upon the reaction of the activated ester and the reactive amine to 
form a stable amide linkage interferes with AL80 measurement and hence mea- 
suring AZ8" nm of the supernatant cannot be rellably used to estimate the 
amount of the uncoupled antibody. 
4. Add 2.5 L of blocking solution to the immunosorbent and mix the contents of the 
flask on a shaker at low speed for 1 h at room temperature. Upon completion of 
the blocking step, allow the gel to settle at RT and remove the supernatant by 
aspiration or decanting. Use care to retain beads in bottle. To ensure complete 
blocking of unused activated sites, repcat the blocking step two times as before. 
The blocking-step supernatant should be saved for the determination of unbound 
antibody. 
5. Add 1000 mL of ligand-coupling buffer to the antibody-coupled beads and mix 
the contents of the flask on a shaker at low speed for 1 h at room temperature. 
Repeat step 5 four to five tlmes to ensure  hat all of the blocking solution has 
been removed. Suspend the immunosorbent in 500 mL of ligand-coupling buffer 
after the final wash step and store at 4OC until further use. 
6. Immunosorbent thus prepared is ready for use and can be packed in col- 
umns by gravity. In the event that the immunosorbent is being prepared for 
future use, store the immunosorbent in Iigand-coupling buffer containing 
0.02% sodium azide. 
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Fig. 2. Antibody coupling to NHS-activated matrix. 
EmphazeTM matrix. Antibody. Stable immunosorbent. 
Fig. 3. Antibody-coupling reaction to Emphaze. 
3.1.2. EMPHAZE JM 
1 .  Refer to the individual lot swell volume value to determine the quantity of beads 
needed for the colun~n. Typically 70-100 mg of dry beads give 1 mI, of swelled 
gel. Weigh out 25 g of dry Emphaze to yield a final sorbent volume of 250 mL 
and transfer it to a l-L polypropylene bottle (.we Fig. 3 for antibody coupling 
reaction). Take necessary precautions in handling dry sorbent. 
2. Prepare 125 mL of an antibody solution at a concentration of 3-5 mg antibody 
per milliliter of coupling buffer and add it directly to the weighed sorbent in the 
bottle. Use antibody-coupling buffer to prepare the antibody solution. Tlzere is no 
need to preswell the beuds prior to use; the coupling buffer will swell tlze bends. 
Gently rock or rotate the bottle to keep the beads suspended and carry out the 
coupling reaction for solution for 1 h at RT or for 24 h at 4°C. Avoid using 
magnetic stir bars because their use may damage the beads. 
3. Centrifuge the contents of the bottle at 1200g for 5-10 min in a bench-top labora- 
tory centrifuge until beads are pelleted. Centrifugation may be done at RT. 
Remove supernatant by aspiration or decanting. Use care to retain beads in bottle. 
This supernatant may be used to determine of the amount of ligand not coupled to 
the beads. Due to use of Triton X- 100 surfactant in production of the beads, there 
may be interference with an A280nm measurement of the uncoupled protein. 
4. Add 500 mL of blocking solution directly to the bottle to quench the unreacted 
azlactone sites. Gently rock or rotate the bottle for 2.5 h. Centrifuge the contents 
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of the bottle at 1200g for 5-10 min or until beads are sedimented. Repeat the 
blocking step three times as outlined in step 4 to ensure complete ~nactivation of 
unused azlactone sites. Remove and save supernatant after centrifugation to 
determine ot unbound antibody. Decant the blocking solution at the end of the 
blocking steps to yield a moist ~mmunosorbent. 
5. Resuspend the immunosorbent in 500 mL of PBS. Rock or rotate sa~llple to keep 
beads suspended in wash solution. Centrifuge samples as in step 4. Repeat step 5 
three to four times and decant the supernatant to yield a moist immunosorbent. 
6 Resuspend the immunosorbent in 500 mL of 1.0 M NaCI. Use of a high-salt wash 
solution, such as 1.0 M NaCI, will remove nonspecifically attached protein. Rock 
or rotate sample to keep beads suspended in 1.0 M NaCl for 30 min. Centrifuge 
samples as in step 4. 
7. Resuspend immunosorbent in 500 mL of ligand-coupling buffer. lmmunosorbent 
thus prepared is ready for use and can be packed in  columns by gravity. In the 
event that the immunosorbent is belng prepared for future use, store the 
immunosorbent in ligand-coupling buffer containing 0.02% sodium azide. 
3. Typical Protocol for lmmunoaffinity Chromatography 
This is a typical protocol for the purification of antigen on an antibody col- 
umn. Some antigens require more or less stringent conditions for dissociation 
f rom an immobilized antibody and conditions for elution may have to  be deter- 
mined experimentally. 
3.2.1. Preparation of the lmmunoaffinity Column for Use 
1. Bring the prepared immunosorbent to room temperature. 
2.  Assemble a column with adapters. Pour the beads from the top with the help of a 
funnel and when packed place the top adapter and connect the tubing (see Fig. 1). 
A jacketed column from Pharmacia with an lnternal diameter of 5.0 cm is recom- 
mended 
3 Equilibrate the column with 10 column volumes (CV) of antigen-loading buffer 
such as 10 mM Tris-HCI buffer, 50 nlM NaCI, pH 7.0 
3.2.2. Sample Application and Elution 
1. Clarlfy and centrifuge the crude sample containing the antigen to be purified by 
low-speed centrifugation and filtering through a 0.45- to 0 . 2 - p  filter. Failure to 
remove cell debris and particulate matter from the feed sample may lead to clog- 
ging and fouling of the immunosorbent. This may lead to shorter shelf hfe of th 
column. 
2. Dilute the crude sample containing the antigen to be purified to total prote 
concentration 5 mg/mL with the antigen-loading buffer. Use OD280 nm to me 
sure the total protein concentration of the crude sample. 
3. Load the sample to the packed immunosorbent at a flow rate of l mL/min. Oper- 
ate the column between h e a r  flow rates (U) of 0.75 to 1.5 crnlmin. For most 
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chromatographic operations 14 is defined as the volumetric flow rate in mL/min 
{Q]/cross-sectional area of the column in cm2 { A ]  where A = 3.14 (R2); R is the 
radius of the column in centimeters. 
4. Wash with the antigen-binding buffer until baseline absorbance at 280 nm is 
reached. 
3.3. Selection of an Elution Strategy 
Antigens and antibodies are bound to each other by a web of forces, which 
include ionic bonding, hydrophobic interactions, hydrogen bonding, and van 
der Waals attractions. The strength of Ag:Ab complexes depends on  the rela- 
tive affinities and avidities of the antibodies. In addition, steric orientation, 
coupling density, and nonspecific interactions can also influence the binding. 
The objective of the elution step is to recover the specifically bound protein at 
a high yield, purity, and stability. Elution conditions, which might denature the 
protein product, have to be avoided. Examination of the current l i t e ra t~~re  sug- 
gests a wide variety of elution conditions and the choice of an eluant seems 
empirical. However, a logical sequence of available elution strategies can be 
considered when selecting an appropriate elution protocol. The  logical 
sequence as follows: 
1. Specific elution: Certain antibodies bind to their respective antigens under high 
pH or in the presence of metals like calcium or magnesium or in the presence of 
chelating agents like EDTA. Antigens bound to such antibodies can be eluted 
under gentle conditions where lowering the pH or adding EDTA to the elution 
buffer or adding divalent metals to the elution buffer causes the Ag:Ab complex 
to disassociate. 
2. Acid elution: This is the most widely used method of desorption and is normally 
very effective. The commonly used acid eluants are glycine-HC1, pH 2.5,0.02 M 
HCI and sodium citrate, pH 2.5. Upon elution, quickly neutralize the pH of the 
eluant sample to 7.0 with 2 M Tris base, pH 8.5, to avoid acid-induced denatur- 
ation. In some cases increased hydrophobic interactions between antigen and anti- 
body gives low recovery with acid elution. Incorporating of 1 M propionic acid, or 
adding 10% dioxane or addition of ethylene glycol to the acid eluant, is effective in 
disassociating such complexes. 
3. Base elution: It is less frequently employed than acid elution. Typically, 1 M 
NH,OH, or 0.05 M diethylamine, pH 11.5 have been employed to elute mem- 
brane proteins (i.e., hydrophobic character) and other antigens that precipitate in 
acid but are stable in basic conditions. 
4. Chaotropic agents: These agents disrupt the tertiary structure of proteins and, 
therefore, can be used to disrupt the Ag:Ab complexes. Chaotropic salts are par- 
ticularly useful as they disrupt ionic interactions, hydrogen bonding, and some- 
times hydrophobic interactions. The relative order of the effectiveness of 
chaotropic anions is SCN->C104->I->Br->Cl-. Chaotropic cations are effective 
in the order of Gu>Mg>K>Na. Eluants such as 8 M urea, 6 M guanidine-HC1, and 
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4 M NaSCN are effective in disrupting most Ag:Ab interactions. To avoid and 
minimize chaotropic salt-induced protein denaturation, rapid desalting or dialy- 
sis of the eluant is advised. 
3.4. Regeneration of the lmmunoaffinity Column 
Wash with 3-4 CV of the 4 M NaCl or glycine-HCl buffer. Store at neutral 
pH in water or buffer containing a preservative, 0.02% sodium azide. 
4. Notes 
1. Before beginning antibody immobilization on commercially available matrices, 
a decision regarding the final immobilized antibody density has to be made. It is 
advisable to aim for immobilized antibody densities between 3-5 mg of antibody 
per milliliter of gel. Immobilizations at high densities > 8 mgImL yield reduced 
antibody utilization due to steric hindrance and overcrowding effects. 
2. It is recommended that a coupling chemistry based on the scale and the strin- , 
gency of the purification is selected. We have routinely purchased commercially 
available activated matrices and provided the coupling instructions are followed. 
little or no problems were encountered. 
3. It is recommended that antibody-coupling efficiency to the support matrix be 
evaluated. Antibody-coupling efficiencies in the range of 75-95% are accept- 
able. If coupling efficiencies less than 70% are attained, check the antibody-cou- 
pling buffers and the antibody samples for the presence of salts like Tris-HC1 or 
glycine. Dialyze the antibody samples extensively to ensure the removal of salts 
like Tris and glycine. Alternatively, choosing another in~mobilization chemistry 
may give higher antibody-coupling efficiencies. 
4. The amount of antibody immobilized on the support matrix is calculated as the 
difference between total antibody added to the gel and the uncoupled antibody 
recovered in the blocking step supernatants and wash pools, as measured by A2*@ 
The antibody-coupling efficiency was calculated as the ratio of [coupled Ab:total 
Ab]. 100%. However certain activation chemistries (NHS or Emphaze) release 
substances as a result of the coupling reaction that may interfere with measure- 
ments at A280 The following protocol may be used to estimate the coupling effi- 
ciency when immobilizing monoclonal antibodies (mAb). Coat Immulon I1 
96-well microtiter plates with 100 Wlwell of 1:200 diluted anti-mouse whole 
molecule in 0.1 M NaHCO, (pH 9.3) for 24 h at 4°C. Wash and aspirate the wells 
with 0.05 M TrisIO. l M NaCl/O.O5% Tween (TBS-Tween) and block the residual 
reactive sites with TBS/O.l% BSA for 20 min at RT. Add various dilutions of 
standard and samples in TBS/O.l% BSA to the wells, 100 JJL in each well and 
incubated for 20 min at 37°C. The concentration of the MAb standard in the 
assay ranges from 50 ng/mL to 0.78 ngImL. Upon incubation, wash the wells 
four times. Add 1:1000 diluted horseradish peroxidase (HRP) conjugated goat 
antimouse IgG to the wells and incubate for 20 min at 37'C. Wash and aspirate 
the wells four times and add 100 pL of OPD substrate to each well. Stop the 
colorimetric reaction after 3 min by the addition of 100 mL of 3 N H2S04 to each 
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well. Bound chromophore can be detected at 490 nm using an EL308 Bio-Tek 
Microplate reader. 
5. The theoretical antigen binding efficiency (vAg) of immobilized monoclonal an- 
tibody (mAb) assuming a 2: 1 antigen to antibody stoichiometry can be calculated 
as follows: 
M = Immobilized MAb density, mg antibodylml of gel 
MW(,Ab, = molecular weight of MAb, 150,000 Daltons 
MW(,,, = molecular weight of antigen being purified, in Daltons 
V = volume of gel, mL 
Theoretical maximum 
antigen binding = [W X [W X (MW,,,,IMW~MA,~) X (211 1 X 100 (1) 
Eq. 1 predicts the theoretical maximum antigen-binding capacity. The amount 
of antigen present in the eluate peaks can be measured by specific antigen assays 
and measurement. Based on the amount of antigen eluted as determined by 
protein assays, the antigen-binding efficiency can be calculated as follows: 
[qAg] = [total amount of eluted antigenltheoretical maximum antigen binding] X 100 
6. It is advisable to calculate the efficiency of the immobilized mAb for the anti- 
gen-antibody system being employed. If the antigen-binding efficiency is too 
low, selecting another coupling chemistry may prove beneficial. However, using 
current immobilization techniques, antigen-binding efficiencies in the range of 
10-30% have been obtained. Selection of site-directed chemistries may offer 
better performance. 
7 .  Also, check for antibody leakage in all column washes and eluants. Tradition- 
ally, CNBr-activated supports have shown to leach some percentage of anchored 
antibody due to the hydrolysis of the isourea linkage. Affi-prep and Emphaze 
show reduced or minimal antibody leaching. 
8. Immobilization procedures outlined in this chapter are applicable to both polyclonal 
and monoclonal antibodies. Antigen-binding efficiencies in the range of 8-15% can 
be expected of polyclonal antibodies using procedures outlined in this chapter. 
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